T7500

Isoxazole (1,2-oxazole) is the inhibitor of acetylcholinesterase (AChE). The ligands of Isoxazole bind to and inhibit the Sxc- antiporter.

TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1].

TGFβ1-IN-3, a diarylhydrazone derivative, inhibits fibroblast activation and proliferation, positioning it as a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).

Mal-Pc, a phthalocyanine-based molecular photosensitizer featuring maleimides, interacts with GSH to diminish its levels and decrease aggregation, enhancing the ROS (Reactive Oxygen Species)-dependent efficacy of photodynamic therapy (PDT) in targeting cancer cells [1].

Antibacterial Agent 128, a siderophore analog-Ciprofloxacin (Ciprofloxacin) conjugate connected via a cleavable linker, demonstrates effective antibiotic properties. Specifically, it exhibits activity against P. aeruginosa and B. pseudomallei, with Minimum Inhibitory Concentration (MIC) values ranging from 0.25 to 64 μg/mL and 1 to 32 μg/mL, respectively [1].

Antidepressant agent 3, an orally active compound, showcases multifaceted pharmacological properties including antidepressant, anxiolytic, performance-enhancing, and nootropic activities [1].

Antidepressant agent 4, an orally active compound, demonstrates efficacy as an antidepressant with additional anxiolytic, performance-enhancing, and nootropic activities [1].

Antitubercular agent 34 (compound 42g) effectively inhibits Mtb H37Rv growth with a MIC 90 value of 1.25 µg/mL and demonstrates resistance to metabolic degradation by human liver microsomes, indicating its potential for tuberculosis research [1].

Antitubercular Agent-35 (compound 42l) is an antitubercular agent effective against Mtb H37Rv and M. Marinum, exhibiting MIC 90 values of 1.25 and 2 μg/mL, respectively. It demonstrates resistance to metabolic degradation by human liver microsomes, rendering it a potential candidate for tuberculosis research [1].

Antitubercular agent-36 (compound 53) is an effective inhibitor of Mycobacterium tuberculosis H37Rv, with a minimum inhibitory concentration (MIC90) of 1.25 μg/mL, and is utilized in tuberculosis research [1].

PPARγ/GR Modulator 1, an orally active dual agonist for the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Glucocorticoid Receptor (GR), exhibits Ki values of 3.3 and 33.6 μM, respectively. This compound is utilized in metabolic disease research, including diabetes [1].